Profit outpacing revenue
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Importance 63 / 95 · growth
EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).
Importance 53 / 95 · profitability
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).
Importance 50 / 95 · cash quality
Classified by the exchange under Healthcare › Healthcare › Healthcare Services › Hospital.
Peer set used on this page: 3 hospital.
Revenue grew 10.7% a year over 7 years, from ₹4,469 cr in FY2019 to ₹9,128 cr in FY2026. Net profit moved from a loss of ₹224 cr in FY2019 to a profit of ₹1,064 cr in FY2026.
Profit grew 31.5% while revenue grew 17.3%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
Net profit grew 31.5% year on year (FY2025 → FY2026).
Revenue grew 17.3% year on year (FY2025 → FY2026).
Revenue has compounded at 10.7% a year over 7 years (₹4,469 → ₹9,128) — steady rather than rapid.
In Q2 FY27 (Jul–Sep 2026), revenue was ₹2,735 cr (up 17.3% on the same quarter last year) and net profit ₹320 cr (down 2.5%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 revenue was ₹2,735 cr, up 17.3% from ₹2,331 cr in Q2 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Q2 FY27 revenue of ₹2,735 cr is the highest of the 17 quarters on record for this company.
Rule QTR_REVENUE_AT_RECORD
Q2 FY27 EBITDA margin was 23.0%, down 1.80 percentage points from 24.8% a year earlier.
Rule QTR_MARGIN_CHANGED_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 1,928 | +14.8% | 254 | +89.5% | 13.2% |
| Q4 FY25 | 2,007 | +12.4% | 188 | −7.4% | 9.4% |
| Q1 FY26 | 2,167 | +16.6% | 267 | +53.3% | 12.3% |
| Q2 FY26 | 2,331 | +17.3% | 329 | +70.3% | 14.1% |
| Q3 FY26 | 2,265 | +17.5% | 197 | −22.4% | 8.7% |
| Q4 FY26 | 2,365 | +17.8% | 271 | +44.2% | 11.5% |
| Q1 FY27 | 2,545 | +17.5% | 273 | +2.3% | 10.7% |
| Q2 FY27 | 2,735 | +17.3% | 320 | −2.5% | 11.7% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 23.4% in FY2026, against 7.1% in FY2019. ROE was 11.0% and ROCE 13.7% in FY2026.
EBITDA margin of 23.4% is the widest in 7 years (prior range 7.1% to 21.3%).
Rule MARGIN_AT_MULTI_YEAR_HIGH
ROE improved from 9.1% to 11.0% year on year.
EBITDA margin improved from 21.3% to 23.4% of revenue.
Debt-to-equity was 0.28x in FY2026, against 0.27x in FY2019; interest coverage 5.36x. Operating cash flow was 1.51x net profit.
Operating cash flow has matched or exceeded reported profit in 5 of the last 5 profit-making years (latest 1.51×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Free cash flow has been positive in 6 of the last 6 years.
Within its 3-company Hospital peer group, it ranks 3 of 3 on return on equity and 2 of 3 on EBITDA margin. Its P/E of 58.7 compares with a peer median of 58.7.
Ranked against 3 hospital (FY2026, consolidated).
FORTIS · 2nd of 3 · set median 17.3%
FORTIS · 2nd of 3 · set median 23.4%
FORTIS · 3rd of 3 · set median 14.3%
FORTIS · 2nd of 3 · set median 58.7×
Trades at 6.13× book — 37% below the hospital median of 9.78×.
Rule PB_BELOW_PEERS
On the trailing twelve months. Last full year: P/E 58.5× · P/S 6.8× · ROE 11.0%.
The share price is down 11.8% over 1 year, up 122% over 3 years (30.4% a year) and up 191% over 5 years (23.9% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 16.7% below its 52-week high.
Over 6 years profit compounded at 50.5% a year while the stock returned 23.9% a year — but FY2020 profit (₹91) was well below the through-cycle level (~₹645), so this rate is inflated by the recovery from a low base.
Rule STOCK_LAGGED_EARNINGS · recovery
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
Nothing is flagged for review for this company.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 9,128 |
| Total income | 4,562 | 4,685 | 4,077 | 5,745 | 6,359 | 6,931 | 7,850 | 9,179 |
| EBITDA | 318 | 662 | 451 | 1,096 | 1,163 | 1,306 | 1,655 | 2,136 |
| Profit before tax | −475 | 227 | −4 | 964 | 792 | 848 | 996 | 1,350 |
| Net profit | −224 | 91 | −56 | 790 | 633 | 645 | 809 | 1,064 |
| EPS (₹) | −3.7 | 0.8 | −0.7 | 7.3 | 7.8 | 7.9 | 10.3 | 13.8 |
| Net worth | 7,112 | 7,206 | 6,718 | 7,008 | 8,100 | 8,556 | 9,169 | 10,169 |
| Total debt | 1,905 | 1,529 | 1,407 | 1,255 | 926 | 858 | 2,475 | 2,873 |
| Operating cash flow | — | — | 486 | 865 | 822 | 1,100 | 1,424 | 1,602 |
| Free cash flow | — | — | 267 | 750 | 397 | 172 | 617 | 673 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 3.6 | -13.0 | 41.9 | 10.1 | 9.5 | 12.9 | 17.3 |
| Profit growth YoY | — | — | — | — | -19.9 | 1.9 | 25.4 | 31.5 |
| Profitability | ||||||||
| EBITDA margin % | 7.1 | 14.3 | 11.2 | 19.2 | 18.5 | 18.9 | 21.3 | 23.4 |
| Net margin % | -4.9 | 2.0 | -1.4 | 13.8 | 10.0 | 9.3 | 10.3 | 11.6 |
| Return on equity % | -3.1 | 1.3 | -0.8 | 11.5 | 8.4 | 7.7 | 9.1 | 11.0 |
| Return on capital % | 0.9 | 4.2 | 1.9 | 9.7 | 9.8 | 10.4 | 12.1 | 13.7 |
| Leverage & cash | ||||||||
| Debt to equity | 0.27 | 0.21 | 0.21 | 0.18 | 0.11 | 0.10 | 0.27 | 0.28 |
| Cash flow ÷ profit | — | — | — | 1.10 | 1.30 | 1.70 | 1.76 | 1.51 |
| Current ratio | 0.62 | 0.62 | 1.25 | 1.32 | 1.39 | 0.69 | 1.35 | 0.86 |